Clinical trial NCT04320459: Alexithymia in Ankylosing Spondylitis
Official title: Alexithymia in Ankylosing Spondylitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ankylosing Spondylitis
Keywords: ankylosing spondylitis
alexithymia
Lead sponsor: Istanbul Medeniyet University
Sponsor class: OTHER
First posted: 2020-03-25
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: The study included 55 patients having AS for at least 1 year diagnosed according to the ASAS classification criteria who presented to our hospital's outpatient clinic and 55 healthy subjects.

Brief summary: The study included 55 patients having Ankylosing Spondylitis (AS) for at least 1 year diagnosed according to the ASAS classification criteria who presented to our hospital's outpatient clinic and 55 healthy subjects. Demographic data were recorded for 55 AS patients who were subsequently assessed using the BASMI (Bath Ankylosing Spondylitis Metrology Index) in terms of elasticity and spinal mobility as well as the BASFI (Bath Ankylosing Spondylitis Functional Index) to determine functional status, the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) to assess the disease activity and the ASQoL (Ankylosing Spondylitis Quality of Life Questionnaire) to evaluate quality of life. The Toronto Alexithymia Scale-20 (TAS-20) was used for assessment of alexithymia and Beck's Depression Inventory (BDI) for depression among patients.

Detailed description: The study included 55 patients having Ankylosing Spondylitis (AS) for at least 1 year diagnosed according to the ASAS classification criteria who presented to our hospital's outpatient clinic and 55 healthy subjects. Demographic data were recorded for 55 AS patients who were subsequently assessed using the BASMI (Bath Ankylosing Spondylitis Metrology Index) in terms of elasticity and spinal mobility as well as the BASFI (Bath Ankylosing Spondylitis Functional Index) to determine functional status, the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) to assess the disease activity and the ASQoL (Ankylosing Spondylitis Quality of Life Questionnaire) to evaluate quality of life. The Toronto Alexithymia Scale-20 (TAS-20) was used for assessment of alexithymia and Beck's Depression Inventory (BDI) for depression among patients.

Eligibility criteria: Inclusion Criteria:

* Diagnosed as AS for at least 1 year according to the ASAS classification criteria
* over 18 years old

Exclusion Criteria:

* fibromyalgia
* age less than 18 years
* vision and hearing impairment
* neurological disease (Parkinson's disease, multiple sclerosis, cerebrovascular disease),
* history of a psychiatric disorder (schizophrenia, bipolar disorder)
* history of chronic condition (DM, thyroid disease) or malignancy

Primary outcomes:
measure: Alexithymia rate in AS patients and controls according to Toronto Alexithymia Scale-20
timeFrame: 7 months
measure: Depression rate in AS patients and controls according to Beck Depression Inventory
timeFrame: 7 months
measure: Relationship between alexithymia and depression and functional indexes (BASFI, BASMI, BASDAI, ASQoL)
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Medeniyet University Faculty of Medicine, Physical Medicine and Rehabilitation Department
Study officials:
References: